These results motivate future studies to assess the therapeutic utility of imipramine in melanoma and other tumor types as an enhancer of tumor immunity in combination with VEGF/VEGFR inhibitors and various immunotherapeutic modalities. This evidence concerns the gene KDR and neoplasm.